research use only

Bedaquiline ATPase inhibitor

Cat.No.S5623

Bedaquiline (TMC-207, R207910), a diarylquinoline, binds to subunit c of mycobacterial ATP synthase and inhibits its activity. It is highly selective for the mycobacterial ATP synthase enzyme compared to the homologous eukaryotic enzyme (Selectivity Index >20 000).
Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 33 mg/mL (59.4 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 555.50 Formula

C32H31BrN2O2

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 843663-66-1 -- Storage of Stock Solutions

Synonyms TMC-207, R207910 SMILES CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
mycobacterial ATP synthase
In vitro
Bedaquiline targets against Mycobacterial ATP synthase complex. This compound has anti-cancer activity, directed against Cancer Stem-like Cells (CSCs). Its treatment of MCF7 breast cancer cells inhibits mitochondrial oxygen-consumption, as well as glycolysis, but induces oxidative stress. It reduces mitochondrial membrane potential, with a significant rise in ROS levels. It specifically inhibits mitochondrial respiration in cancer cells, while enhancing mitochondrial function in normal cells. This chemical dramatically inhibits oxygen consumption and ATP production in the low micromolar range. In addition, its treatment also reduced aerobic glycolysis.
In vivo
Bedaquiline follows triphasic elimination and characterized by an outstandingly long terminal half-life, around 173 h in humans.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-30)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07675954 NOT_YET_RECRUITING
Rifampicin-Resistant Tuberculosis
Seoul National University Hospital
2026-10-01 PHASE3
NCT06441006 RECRUITING
Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
University of California, San Francisco
2025-10-03 PHASE2; PHASE3
NCT07485010 NOT_YET_RECRUITING
Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
The University of Queensland
2027-04 PHASE2
NCT07486024 NOT_YET_RECRUITING
MDR-TB; Tuberculosis Multi Drug Resistant Active; Antibiotic Resistance; Mycobacterium Tuberculosis
Assistance Publique - Hôpitaux de Paris
2026-04 PHASE3
NCT07076225 NOT_YET_RECRUITING
Pulmonary Tuberculosis
Shenzhen Third People's Hospital
2025-07-25 PHASE3
NCT04310930 RECRUITING
Pulmonary Disease Due to Mycobacteria (Diagnosis)
The University of Queensland
2020-03-02 PHASE2; PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map